| Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis. | |
| | |
MedLine Citation:
|
PMID: 9058624 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In primary biliary cirrhosis (PBC), liver damage results from both immune- and bile acid-mediated mechanisms. Therapies directed against the former have been either ineffective or toxic, while bile salt therapy is well tolerated but of uncertain long-term benefit. Because of slow disease progression, there is a need for surrogate markers of long-term efficacy. Candidates include markers of immune activation, such as soluble intercellular adhesion molecule-1 (sICAM-1) which shows promise in this respect. Using this marker, evidence has been presented to suggest an additive effect of the combination of ursodeoxycholic acid (UDCA) with azathioprine and prednisone in a short-term trial in PBC. |
| | |
Authors:
|
J S de Caestecker |
Related Documents
:
|
8015354 - Inhibition of rat liver microsomal bilirubin udp-glucuronosyltransferase by ursodeoxych... 16432164 - Enhancement of dna topoisomerase i inhibitor-induced apoptosis by ursodeoxycholic acid. 8412364 - Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutami... 641034 - Isolation of 3beta,7alpha-dihydroxychol-5-enoic acid, an intermediate of chenodeoxychol... 503454 - Metalloporphyrins and molecular complexes of amino acids with porphyrins in juvenile vo... 9986914 - Effects of sulfur dioxide on lichen lipids and fatty acids. |
Publication Detail:
|
Type: Comment; Journal Article |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 9 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 1997 Feb |
Date Detail:
|
Created Date: 1997-03-25 Completed Date: 1997-03-25 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 145-7 Citation Subset: IM |
Affiliation:
|
Glenfield Hospital, Leicester, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use* Azathioprine / therapeutic use Biological Markers / analysis Cholagogues and Choleretics / therapeutic use* Drug Therapy, Combination Humans Immunosuppressive Agents / therapeutic use* Intercellular Adhesion Molecule-1 / analysis* Liver Cirrhosis, Biliary / drug therapy*, immunology*, physiopathology Prednisone / therapeutic use Ursodeoxycholic Acid / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Biological Markers; 0/Cholagogues and Choleretics; 0/Immunosuppressive Agents; 126547-89-5/Intercellular Adhesion Molecule-1; 128-13-2/Ursodeoxycholic Acid; 446-86-6/Azathioprine; 53-03-2/Prednisone |
| Comments/Corrections | |
Comment On:
|
Eur J Gastroenterol Hepatol. 1997 Feb;9(2):155-61
[PMID:
9058626
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of surgery in the major early complications of severe acute pancreatitis.
Next Document: Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic ac...